

OCT 31 2007

Application No. 10/693,056  
Amdt. Dated October 31, 2007  
Amendment under 37 CFR 1.116 Expedited Procedure  
Examining Group 1639

PATENT**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1-94. (Canceled)

95. (Currently amended) A method for producing a polypeptide, said method comprising,

expressing a nucleic acid encoding a polypeptide, thereby recombinantly expressing the polypeptide;

wherein the polypeptide comprises a first LDL-receptor class A monomer domain variant and a second LDL-receptor class A monomer domain variant,

wherein each of the first and second LDL-receptor class A monomer domain variants ~~have non-naturally-occurring~~ consists of an amino acid sequences that is not present in any naturally-occurring A monomer domain,

wherein the first and second LDL-receptor class A monomer domain variants each have a binding specificity for a target molecule,

wherein the two domain variants are linked by a heterologous linker, and

wherein each of first and second the LDL-receptor class A monomer domain variants comprise the following sequence:

C-X<sub>(3-15)</sub>-C-X<sub>(4-15)</sub>-C-X<sub>(6-7)</sub>-C-[N,D]-X<sub>(3)</sub>-[D,E,N,Q,H,S,T]-C-X<sub>(4-6)</sub>-D-E-X<sub>(2-3)</sub>-C  
(SEQ ID NO:331).

96. (Previously presented) The method of claim 95, wherein the nucleic acid is expressed in a bacterial cell.

97. (Previously presented) The method of claim 96, wherein the bacterial cell is an *E. coli* cell.

Application No. 10/693,056  
Amdt. Dated October 31, 2007  
Amendment under 37 CFR 1.116 Expedited Procedure  
Examining Group 1639

PATENT

98. (Previously presented) The method of claim 95, wherein the nucleic acid is expressed on the surface of a phage.

99. (Withdrawn) The method of claim 95, wherein the nucleic acid is expressed in a mammalian cell.

100. (Previously presented) The method of claim 95, further comprising submitting the polypeptide to conditions that refold the polypeptide.

101. (Previously presented) The method of claim 95, further comprising dialyzing the polypeptide.

102. (Withdrawn) The method of claim 95, wherein the first LDL-receptor class A monomer domain variant has binding specificity for a binding site on a first target molecule and the second LDL-receptor class A monomer domain variant has binding specificity for a binding site on a second target molecule.

103. (Previously presented) The method of claim 95, wherein the first LDL-receptor class A monomer domain variant has binding specificity for a first binding site on a target molecule and the second LDL-receptor class A monomer domain variant has binding specificity for a second binding site on the same target molecule.

104. (Withdrawn) The method of claim 95, wherein the polypeptide further comprises a third LDL receptor class A monomer domain variant.

105. (Withdrawn) The method of claim 104, wherein the polypeptide further comprises a fourth LDL receptor class A monomer domain variant.

106. (Previously presented) The method of claim 95, wherein the LDL receptor class A monomer domain variants are derived from human monomer domains.

Application No. 10/693,056  
Amdt. Dated October 31, 2007  
Amendment under 37 CFR 1.116 Expedited Procedure  
Examining Group 1639

PATENT

107. (Previously presented) The method of claim 95, wherein the heterologous linker is between 1-20 amino acids.